Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 8, 2025

Primary Completion Date

July 2, 2025

Study Completion Date

July 2, 2025

Conditions
Healthy Volunteer Study
Interventions
DRUG

Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR

"Treatment-A (Digoxin): A single dose of digoxin will be administered under fasting conditions.~Treatment-B (Digoxin + BEM/RZR): A single dose of digoxin will be co-administered a single dose of BEM/RZR under fasting conditions.~Treatment-C (Digoxin + 2h BEM/RZR): A single dose of digoxin will be administered under fasting conditions. Then, a single dose of BEM/RZR will be administered approximately 2 hours later under fasting conditions."

DRUG

Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR

"Treatment-D (rosuvastatin): A single dose of rosuvastatin will be administered under fasting conditions.~Treatment-E (rosuvastatin + BEM/RZR): A single dose of rosuvastatin will be co-administered with a single dose BEM/RZR under fasting conditions.~Treatment-F (rosuvastatin + 2h BEM/RZR): A single dose of rosuvastatin will be administered under fasting conditions. Then, a single dose BEM/RZR will be administered approximately 2 hours later under fasting conditions."

Trial Locations (1)

Unknown

Atea Study Site, Québec

Sponsors
All Listed Sponsors
lead

Atea Pharmaceuticals, Inc.

INDUSTRY

NCT06921941 - Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin | Biotech Hunter | Biotech Hunter